IP Library Patent Application 12442819
Patent Application
App. No. 12/442,819

SUBMICRON NANOPARTICLE OF POORLY WATER SOLUBLE CAMPTOTHECIN DERIVATIVES AND PROCESS FOR PREPARATION THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/442,819
Abstract

The present invention relates to a nanoparticle composition comprising a camptothecin derivative, solid polyethyleneglycol and an anti-associative agent, and the process for preparing the same. Specifically, the present invention provides a composition comprising a nanoparticle of the camptothecin derivative, which is prepared by solid-dispersing the poorly water soluble camptothecin derivative in polyethyleneglycol and dissolving the solid dispersions in an aqueous solution containing an anti-associative agent. The composition of the present invention stabilizes the camptothecin derivative lactone form in body fluid for effective anticancer activity.

Claims (21)

1 . A nanoparticle composition of a camptothecin derivative, which comprises the camptothecin derivative, solid polyethyleneglycol, and an anti-associative agent selected from solid amphiphilic block copolymer and solid surfactant.

2 . The composition of claim 1 wherein the camptothecin derivative is a compound having a water solubility of 10 μg/Ml or less.

3 . The composition of claim 1 wherein the camptothecin derivative is camptothecin or 7-ethyl-10-hydroxycamptothecin.

4 . The composition of claim 1 wherein polyethyleneglycol has a weight average molecular weight of 1,500 to 20,000 Dalton.

5 . The composition of claim 1 wherein both ends of polyethyleneglycol are protected by a hydroxy, alkyl or acyl group.

6 . The composition of claim 1 wherein polyethyleneglycol is contained in an amount of 50 to 1000 folds the weight of the camptothecin derivative.

7 . The composition of claim 1 wherein the amphiphilic block copolymer is the A-B type di-block copolymer wherein the hydrophilic block (A) has a weight average molecular weight in the range of 1,000 to 10,000 Dalton, and the hydrophobic block (B) has a weight average molecular weight in the range of 500 to 10,000 Dalton.

8 . The composition of claim 7 wherein the hydrophilic block (A) is polyethyleneglycol or monomethoxy polyethyleneglycol, and the hydrophobic block (B) is selected from a group consisting of polylactic acid, polycaprolactone, copolymer of lactic acid and glycolic acid, polydioxan-2-one, and copolymer of lactic acid and 1,4-dioxan-2-one.

9 . The composition of claim 7 wherein the hydrophilic block (A) is monomethoxy polyethyleneglycol, and one selected from a group consisting of lauric acid, palmitoic acid, stearic acid, oleic acid, tocopherol succinate and cholesterol succinate is added to the end of the hydrophobic block (B) via an ester bond.

10 . The composition of claim 1 wherein the solid surfactant is polyethyleneglycol tocopherol succinate whose polyethyleneglycol has a weight average molecular weight of 1,000 to 5,000 Dalton.

11 . The composition of claim 1 wherein each anti-associative agent is contained in an amount of 1 to 400 times the weight of the camptothecin derivative.

12 . The composition of claim 1 wherein the size of nanoparticle is in the range of 100 to 1000 nm.

13 . The composition of claim 1 wherein the nanoparticle composition is present in the freeze-dried form.

14 . The composition of claim 1 , which further comprises a pharmaceutically acceptable carrier, and is used for treating cancer.

15 . A process for preparing the nanoparticle composition according to claim 1 , which comprises the steps of

(a) melting a camptothecin derivative in solid polyethyleneglycol;

(b) forming a solid dispersion by cooling the melt obtained in step (a); and

(c) dissolving the solid dispersion obtained in step (b) in an aqueous solution of solid amphiphilic block copolymer or solid surfactant.

16 . The process of claim 15 , which comprises a further step for freeze-drying the aqueous solution obtained in step (c).

17 . The process of claim 15 wherein the melting temperature in step (a) is 60˜180° C.

18 . The process of claim 15 wherein an organic solvent selected from methanol, ethanol, dichloromethane, acetone and acetonitrile is used in step (a), and the organic solvent is removed under reduced pressure.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2012
From: SAMYANG CORPORATION
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 029142/0899 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2009
From: KANG, HYE WON; YIM, EUN YOUNG; SEO, MIN HYO
To: SAMYANG COPORATION
Reel/Frame 022515/0829 →